1. Scrip

Coronavirus Update: AstraZeneca To Develop Oxford’s Vaccine, Adaptive Trial Delivers Remdesivir's Good News

More Details From China's Negative Results In Lancet

 
• By Scrip Team

AstraZeneca is to develop and distribute Oxford's COVID-19 vaccine candidate in collaboration with Vaccitech. Its developers believe it could be available as early as September.

AZ_Courtyard
AstraZeneca's new HQ is in Cambridge, but has a longstanding basic research relationship with the University of Oxford

AstraZeneca PLC has signed a partnership with the Oxford University-led group which has emerged as a potential frontrunner in the race to develop a vaccine for COVID-19.

The UK-headquartered company has agreed to oversee global development and distribution of the university’s recombinant adenovirus

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from COVID-19

More from Scrip